# 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection

> **NCT02959255** · PHASE4 · COMPLETED · sponsor: **Elpen Pharmaceutical Co. Inc.** · enrollment: 364 (actual)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT02959255
- **Lead sponsor:** Elpen Pharmaceutical Co. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-30
- **Primary completion:** 2017-12-30
- **Final completion:** 2017-12-30
- **Target enrollment:** 364 (ACTUAL)
- **Last updated:** 2018-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02959255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02959255, "10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02959255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*